Hy's law: predicting serious hepatotoxicity.
US Food and Drug Administration. robert.temple@hhs.fda.gov
Robert
R
Temple
D016907:Adverse Drug Reaction Reporting Systems; D000410:Alanine Transaminase / Q000097:blood; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D001384:Azetidines / Q000009:adverse effects; D001577:Benzophenones / Q000009:adverse effects; D001596:Benzylamines / Q000009:adverse effects; D001663:Bilirubin / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001969:Bromobenzenes / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000201:enzymology / Q000209:etiology*; D002839:Chromans / Q000009:adverse effects; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D045162:Thiazolidinediones / Q000009:adverse effects; D000077288:Troglitazone; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D001384:Azetidines; D001577:Benzophenones; D001596:Benzylamines; D015415:Biomarkers; D001969:Bromobenzenes; D002839:Chromans; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; C426686:ximelagatran; C053083:bromfenac; D000410:Alanine Transaminase; D000077288:Troglitazone; D001663:Bilirubin